Recently, we identified several novel TCRs specific to the HLA-A2 restricted Alpha-fetoprotein epitope (AFP158) and showed that human T cells engineered with such TCR genes could recognize and kill AFP+ HepG2 tumor cells, which resulted in regression of HCC xenografts in immunocompromised NSG mice (9). The gene discussed is AFP; the disease is hepatocellular carcinoma.